Allurion reports weight loss and muscle gain with new therapy

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a medical company focused on obesity treatment currently trading near its 52-week low at $2.27, has announced promising initial results from a new therapeutic approach combining their Allurion Program with low-dose GLP-1 therapy. According to InvestingPro data, while the company maintains impressive gross profit margins of 73%, it faces significant challenges with cash burn and debt management. The combined treatment was tested on 52 patients, who showed an average total weight loss of 20.3% and an increase in lean body mass of 15% after 8 months.

The Allurion Program includes a swallowable gastric balloon, which is part of a broader weight-loss platform that also features virtual care and a behavior change program. With revenue of $34.75 million in the last twelve months, the company’s innovative approach has garnered attention despite a challenging market environment. The study began with patients undergoing balloon therapy for one month, followed by the addition of 0.25mg of the drug semaglutide, a GLP-1 medication. Over the next six months, the dose was gradually increased but did not exceed 1.0mg.

Dr. Luigi Flagiello, a bariatric surgeon involved in the study, noted the dual benefits of the Allurion Balloon in inducing satiety and semaglutide in reducing hunger. He highlighted that the low-dose GLP-1 therapy led to fewer side effects, such as muscle wasting, and improved patient adherence to the medication.

This initial data suggests a potential shift in the standard of care for patients seeking weight loss without significant muscle loss. The company’s CEO, Dr. Shantanu Gaur, expressed optimism about building upon these results and the possibility of establishing a new standard for metabolically healthy weight loss. For investors interested in deeper analysis, InvestingPro offers comprehensive research reports with 18+ additional ProTips and detailed financial metrics that could help evaluate the company’s growth potential.

Previous studies have shown that GLP-1 therapies can result in a significant reduction in lean mass and that many patients discontinue these medications due to side effects, dose escalation, and cost. The Allurion approach aims to address these challenges by using lower doses of GLP-1s and leveraging their full program.

Further data from the ongoing case series is expected to be presented at future medical meetings. The Allurion Gastric Balloon is currently an investigational device in the United States. With the next earnings report due on March 21, 2025, investors can access detailed financial analysis and Fair Value estimates through InvestingPro’s comprehensive research tools.

This report is based on a press release statement from Allurion Technologies, Inc.

In other recent news, Allurion Technologies, Inc. announced a $6.1 million stock and warrant sale through a registered direct offering and a concurrent private placement. The proceeds are intended for clinical pipeline funding, working capital, and general corporate purposes. Additionally, the company has disclosed plans to conduct a clinical study on the combined use of the Allurion Balloon and GLP-1 agonists to improve long-term adherence and tolerability to GLP-1 therapy. This study aims to address the significant reduction in lean mass often seen with GLP-1 therapy, a prevalent issue in obesity treatment. Allurion’s approach includes the Allurion Program, which merges the Allurion Gastric Balloon and Virtual Care Suite. Moreover, Allurion has secured a new U.S. patent for its gastric balloon technology, enhancing the precision of the valve system that controls the balloon’s deployment. This patent is expected to protect the company’s technology through July 2039, adding to its portfolio of 20 U.S. patents. These developments reflect Allurion’s commitment to innovation in non-surgical weight loss treatments and its ongoing efforts to expand its intellectual property portfolio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.